Roche further trims applied sciences offering with Cellavista sale
This article was originally published in Clinica
Executive Summary
Roche is selling its Cellavista imaging system, which is used to analyse cell cultures in research, back to the technology's developer SynenTec (Penzberg, Germany). The deal is consistent with Roche's efforts to scale-back its Applied Sciences division; the company declined to say how much the deal was worth or why it has decided to offload Cellavista specifically.